Loading…
OriginalArticle : Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance
Background: Incretin-based therapies are rapidly becoming one of the main glycemic control strategies in diabetes. Considering the large numbers of papillary thyroid carcinomas (PTCs) and possible effects of glucagon-like peptide-1 (GLP-1) on cell proliferation, the expression of GLP-1 receptor (GLP...
Saved in:
Published in: | Endocrinology and metabolism (Seoul) 2014-12, Vol.29 (4), p.536 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | Korean |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | |
container_issue | 4 |
container_start_page | 536 |
container_title | Endocrinology and metabolism (Seoul) |
container_volume | 29 |
creator | Min Jung Jung Su Kyoung Kwon |
description | Background: Incretin-based therapies are rapidly becoming one of the main glycemic control strategies in diabetes. Considering the large numbers of papillary thyroid carcinomas (PTCs) and possible effects of glucagon-like peptide-1 (GLP-1) on cell proliferation, the expression of GLP-1 receptor (GLP-1R) in PTC is likely to have clinical significance. We performed this study to evaluate the expression of GLP-1R in PTC and the clinical meaning of GLP-1R expression in PTC. Methods: Fifty-six cases of PTC, four cases of medullary thyroid cancer (MTC), seven cases of nodular hyperplasia and 56 normal thyroid tissue samples were selected for immunostaining for GLP-1R. Clinical parameters were obtained by retrospective review of medical records. Results: Immunohistochemical staining for GLP-1R showed immunoreactivity in 18 of 56 cases of PTC (32.1%). All four cases of MTC exhibited cytoplasmic GLP-1R expression. Nodular hyperplasia exhibited immunoreactivity in two of seven cases (28.6%). All normal thyroid follicular cells showed negative immunoreactivity. In univariable and multivariable analyses, tumor multifocality was negatively correlated with GLP-1R expression. Extrathyroidal extension showed positive association with GLP-1R expression that was almost significant. Sex, age, tumor size, and lymph node metastasis were not significantly associated with GLP-1R expression. Conclusion: Some parts of PTC tissues express GLP-1R, and GLP-1R expression in PTC was negatively correlated with tumor multifocality. The long-term influence of pharmacologically increased GLP-1 on thyroid follicular cells and development and progression of tumors originating from thyroid follicular cells should be investigated. |
format | article |
fullrecord | <record><control><sourceid>kiss</sourceid><recordid>TN_cdi_kiss_primary_3295003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><kiss_id>3295003</kiss_id><sourcerecordid>3295003</sourcerecordid><originalsourceid>FETCH-kiss_primary_32950033</originalsourceid><addsrcrecordid>eNp9jM1Kw0AURmdRoUX7BG7uCwTy00rTnYRWBcGiXXRXLpNJ-tnpvcNMBPsCPrdZuPbbnAMHvomZlXldZcv64TA185Q-83Gr1aIoi5n5eYvoIewf4wDrHa1p8x2iSwkqpB09-S_LvUr2irOjnQsDWpcV9O7s6BoJQjsO8J7jlfana1S01HC0EL0wsbT0MiRqPARWAw8n9drD0gd6QQfLYt2duenYJzf_46253272zXN2RkrHEHEZ349VWS_zvKr-r7_qJk0b</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>OriginalArticle : Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance</title><source>PubMed (Medline)</source><creator>Min Jung Jung ; Su Kyoung Kwon</creator><creatorcontrib>Min Jung Jung ; Su Kyoung Kwon</creatorcontrib><description>Background: Incretin-based therapies are rapidly becoming one of the main glycemic control strategies in diabetes. Considering the large numbers of papillary thyroid carcinomas (PTCs) and possible effects of glucagon-like peptide-1 (GLP-1) on cell proliferation, the expression of GLP-1 receptor (GLP-1R) in PTC is likely to have clinical significance. We performed this study to evaluate the expression of GLP-1R in PTC and the clinical meaning of GLP-1R expression in PTC. Methods: Fifty-six cases of PTC, four cases of medullary thyroid cancer (MTC), seven cases of nodular hyperplasia and 56 normal thyroid tissue samples were selected for immunostaining for GLP-1R. Clinical parameters were obtained by retrospective review of medical records. Results: Immunohistochemical staining for GLP-1R showed immunoreactivity in 18 of 56 cases of PTC (32.1%). All four cases of MTC exhibited cytoplasmic GLP-1R expression. Nodular hyperplasia exhibited immunoreactivity in two of seven cases (28.6%). All normal thyroid follicular cells showed negative immunoreactivity. In univariable and multivariable analyses, tumor multifocality was negatively correlated with GLP-1R expression. Extrathyroidal extension showed positive association with GLP-1R expression that was almost significant. Sex, age, tumor size, and lymph node metastasis were not significantly associated with GLP-1R expression. Conclusion: Some parts of PTC tissues express GLP-1R, and GLP-1R expression in PTC was negatively correlated with tumor multifocality. The long-term influence of pharmacologically increased GLP-1 on thyroid follicular cells and development and progression of tumors originating from thyroid follicular cells should be investigated.</description><identifier>ISSN: 2093-596X</identifier><language>kor</language><publisher>대한내분비학회</publisher><subject>Clinical significance ; Glucagon-like peptide-1 receptor ; Incretin-based therapy ; papillary ; Thyroid cancer</subject><ispartof>Endocrinology and metabolism (Seoul), 2014-12, Vol.29 (4), p.536</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Min Jung Jung</creatorcontrib><creatorcontrib>Su Kyoung Kwon</creatorcontrib><title>OriginalArticle : Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance</title><title>Endocrinology and metabolism (Seoul)</title><addtitle>Endocrinology and Metabolism</addtitle><description>Background: Incretin-based therapies are rapidly becoming one of the main glycemic control strategies in diabetes. Considering the large numbers of papillary thyroid carcinomas (PTCs) and possible effects of glucagon-like peptide-1 (GLP-1) on cell proliferation, the expression of GLP-1 receptor (GLP-1R) in PTC is likely to have clinical significance. We performed this study to evaluate the expression of GLP-1R in PTC and the clinical meaning of GLP-1R expression in PTC. Methods: Fifty-six cases of PTC, four cases of medullary thyroid cancer (MTC), seven cases of nodular hyperplasia and 56 normal thyroid tissue samples were selected for immunostaining for GLP-1R. Clinical parameters were obtained by retrospective review of medical records. Results: Immunohistochemical staining for GLP-1R showed immunoreactivity in 18 of 56 cases of PTC (32.1%). All four cases of MTC exhibited cytoplasmic GLP-1R expression. Nodular hyperplasia exhibited immunoreactivity in two of seven cases (28.6%). All normal thyroid follicular cells showed negative immunoreactivity. In univariable and multivariable analyses, tumor multifocality was negatively correlated with GLP-1R expression. Extrathyroidal extension showed positive association with GLP-1R expression that was almost significant. Sex, age, tumor size, and lymph node metastasis were not significantly associated with GLP-1R expression. Conclusion: Some parts of PTC tissues express GLP-1R, and GLP-1R expression in PTC was negatively correlated with tumor multifocality. The long-term influence of pharmacologically increased GLP-1 on thyroid follicular cells and development and progression of tumors originating from thyroid follicular cells should be investigated.</description><subject>Clinical significance</subject><subject>Glucagon-like peptide-1 receptor</subject><subject>Incretin-based therapy</subject><subject>papillary</subject><subject>Thyroid cancer</subject><issn>2093-596X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp9jM1Kw0AURmdRoUX7BG7uCwTy00rTnYRWBcGiXXRXLpNJ-tnpvcNMBPsCPrdZuPbbnAMHvomZlXldZcv64TA185Q-83Gr1aIoi5n5eYvoIewf4wDrHa1p8x2iSwkqpB09-S_LvUr2irOjnQsDWpcV9O7s6BoJQjsO8J7jlfana1S01HC0EL0wsbT0MiRqPARWAw8n9drD0gd6QQfLYt2duenYJzf_46253272zXN2RkrHEHEZ349VWS_zvKr-r7_qJk0b</recordid><startdate>20141231</startdate><enddate>20141231</enddate><creator>Min Jung Jung</creator><creator>Su Kyoung Kwon</creator><general>대한내분비학회</general><scope>HZB</scope><scope>Q5X</scope></search><sort><creationdate>20141231</creationdate><title>OriginalArticle : Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance</title><author>Min Jung Jung ; Su Kyoung Kwon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kiss_primary_32950033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>2014</creationdate><topic>Clinical significance</topic><topic>Glucagon-like peptide-1 receptor</topic><topic>Incretin-based therapy</topic><topic>papillary</topic><topic>Thyroid cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Min Jung Jung</creatorcontrib><creatorcontrib>Su Kyoung Kwon</creatorcontrib><collection>KISS(한국학술정보)</collection><collection>Korean Studies Information Service System (KISS) B-Type</collection><jtitle>Endocrinology and metabolism (Seoul)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Min Jung Jung</au><au>Su Kyoung Kwon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>OriginalArticle : Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance</atitle><jtitle>Endocrinology and metabolism (Seoul)</jtitle><addtitle>Endocrinology and Metabolism</addtitle><date>2014-12-31</date><risdate>2014</risdate><volume>29</volume><issue>4</issue><spage>536</spage><pages>536-</pages><issn>2093-596X</issn><abstract>Background: Incretin-based therapies are rapidly becoming one of the main glycemic control strategies in diabetes. Considering the large numbers of papillary thyroid carcinomas (PTCs) and possible effects of glucagon-like peptide-1 (GLP-1) on cell proliferation, the expression of GLP-1 receptor (GLP-1R) in PTC is likely to have clinical significance. We performed this study to evaluate the expression of GLP-1R in PTC and the clinical meaning of GLP-1R expression in PTC. Methods: Fifty-six cases of PTC, four cases of medullary thyroid cancer (MTC), seven cases of nodular hyperplasia and 56 normal thyroid tissue samples were selected for immunostaining for GLP-1R. Clinical parameters were obtained by retrospective review of medical records. Results: Immunohistochemical staining for GLP-1R showed immunoreactivity in 18 of 56 cases of PTC (32.1%). All four cases of MTC exhibited cytoplasmic GLP-1R expression. Nodular hyperplasia exhibited immunoreactivity in two of seven cases (28.6%). All normal thyroid follicular cells showed negative immunoreactivity. In univariable and multivariable analyses, tumor multifocality was negatively correlated with GLP-1R expression. Extrathyroidal extension showed positive association with GLP-1R expression that was almost significant. Sex, age, tumor size, and lymph node metastasis were not significantly associated with GLP-1R expression. Conclusion: Some parts of PTC tissues express GLP-1R, and GLP-1R expression in PTC was negatively correlated with tumor multifocality. The long-term influence of pharmacologically increased GLP-1 on thyroid follicular cells and development and progression of tumors originating from thyroid follicular cells should be investigated.</abstract><pub>대한내분비학회</pub><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2093-596X |
ispartof | Endocrinology and metabolism (Seoul), 2014-12, Vol.29 (4), p.536 |
issn | 2093-596X |
language | kor |
recordid | cdi_kiss_primary_3295003 |
source | PubMed (Medline) |
subjects | Clinical significance Glucagon-like peptide-1 receptor Incretin-based therapy papillary Thyroid cancer |
title | OriginalArticle : Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-22T10%3A20%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kiss&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=OriginalArticle%20:%20Expression%20of%20Glucagon-Like%20Peptide-1%20Receptor%20in%20Papillary%20Thyroid%20Carcinoma%20and%20Its%20Clinicopathologic%20Significance&rft.jtitle=Endocrinology%20and%20metabolism%20(Seoul)&rft.au=Min%20Jung%20Jung&rft.date=2014-12-31&rft.volume=29&rft.issue=4&rft.spage=536&rft.pages=536-&rft.issn=2093-596X&rft_id=info:doi/&rft_dat=%3Ckiss%3E3295003%3C/kiss%3E%3Cgrp_id%3Ecdi_FETCH-kiss_primary_32950033%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_kiss_id=3295003&rfr_iscdi=true |